MedTrace Logo

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

NCT04750759 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2021-12-09

No results posted yet for this study

Summary

Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.

Conditions

  • Covid19

Interventions

DRUG

Niclosamide + Camostat

Niclosamide will be applied in combination with camostat.

OTHER

Placebo

Placebo to interventional drug

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Charité Research Organisation GmbH

    lead OTHER

Principal Investigators

  • Martin Witzenrath, Prof. · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750759 on ClinicalTrials.gov